H.C. Wainwright raised the firm’s price target on Delcath Systems (DCTH) to $31 from $29 and keeps a Buy rating on the shares following the Q2 report. The firm says robust Hepzato adoption continues to drive growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH: